Human chronic myelogenous leukemia (CML) is characterized by a translocation between chromosomes 9 and 22 that results in a BCR-ABL fusion gene coding for chimeric proteins. The junctional region of the BCR-ABL b3a2 molecule represents a potential leukemia-specific antigen which could be recognized by cytotoxic T lymphocytes (CTL). In fact, we identified a junctional nonapeptide (SSKALQRPV) which binds to HLA-A2.1 molecules. This peptide, as well as those binding to HLA-A3, -A11, and -B8 molecules (previously identified by others), elicits primary CTL responses in vitro from PBLs of both healthy donors and CML patients. Such CTL recognize HLA-matched, BCR-ABL-positive leukemic cells, implying efficient natural processing and presentation of these junctional peptides. Specific CTL were found at high frequency in 5 of 21 CML patients, suggesting that these epitopes are, to some extent, immunogenic in vivo during the course of the disease. These peptides could be useful for the development of specific immunotherapy in CML patients. ( J. Clin. Invest. 1998. 101:2290-2296.)
Introduction
Cytotoxic T lymphocytes (CTL) 1 are potent effectors of the immune system that could provide long-term antitumor protection if induced by appropriate vaccines. CTL recognize 8-14 amino acid peptides, processed intracellularly and presented by MHC class I molecules (1) . Several criteria qualify a peptide, derived from a particular protooncogene product, as a potential immunotherapeutic agent. The peptide needs to bind to MHC class I or class II molecules. Most importantly, the MHC/peptide complex should be presented at the surface of cancer cells in sufficient quantity to elicit CTL responses and to render these tumors susceptible to T cell-mediated lysis. Finally, self-tolerance constraints should not preclude the emergence of specific T cells.
In animal models, both helper T lymphocytes and CTL participate in the rejection of murine leukemia virus (MuLV)-induced tumors (2, 3) . Furthermore, vaccination with MuLV antigens accelerates tumor rejection in vivo (4) . Finally, adoptive transfer of CTL, specifically recognizing MuLV antigens, eradicates disseminated leukemias (5, 6) . The absence of well characterized human leukemia antigens, selectively expressed by malignant cells and recognizable by T cells, has prevented the development of immunotherapy.
The rearrangement of the bcr and abl genes, in Philadelphia chromosome-positive (Ph1 ϩ ) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (7) (8) (9) (10) (11) (12) (13) (14) (15) , results in the expression of a BCR-ABL fusion protein which represents a leukemia-specific antigen of potential immunotherapeutical interest. In CML, the translocation between chromosomes 9 and 22 (q34, q11) is present in Ͼ 95% of patients (7) . In CML, the breakpoint on chromosome 22 is located between either bcr exons b2 and b3 or b3 and b4 (10) . Accordingly, after junction with abl exon 2 (a2), two distinct p210 chimeric BCR-ABL proteins (BCR-ABL b2A2 and BCR-ABL b3A2 ) are produced, both carrying tyrosine kinase activity (9) . In this context, it has been shown that peptides from the joining region of the hybrid molecule BCR-ABL b3a2 (the most frequently observed), induce specific antibodies to BCR-ABL (16), and a CD4 cellular immune response in mice (17) and humans (18) . Four different peptides from the junction region have already been identified that bind with either intermediate or high affinity to HLA-A3, -A11, -B8, or both HLA-A3 and -A11 molecules (19) (20) (21) and elicit CTL in vitro. However, these studies failed to evidence junction peptide presentation by HLA-A2.1, the most frequent MHC class I allele in the human species, and did not provide evidence of natural CTL responses against these peptides in CML patients.
In this study we examined whether the chimeric BCR-ABL b3a2 protein serves as a tumor-specific antigen in normal donors and in CML patients. We identified one peptide within the BCR-ABL b3a2 chimeric protein that binds to HLA-A2.1 molecules. We observed that this peptide, as well as the four peptides that have already been described (19) (20) (21) , elicit in vitro peptide-specific MHC class I-restricted CTL response in HLA-matched healthy donors and CML patients. These peptide-induced CTL lysed HLA-matched BCR-ABL b3a2 positive tumor cells, implying efficient intracellular processing and presentation of the fusion protein. Finally, we have detected CTL that recognize specifically BCR-ABL positive autologous tumors in the peripheral blood of 5 of 21 CML patients, indicating that immunization occurs spontaneously in vivo, at least in some CML patients.
Methods
Human cells. PBLs were harvested from buffy coats by centrifugation (600 g , 20 min, room temperature) over a Ficoll-Hypaque solution (Pharmacia, Uppsala, Sweden) and stored in liquid nitrogen. Healthy donors and patients were screened for HLA-A3, -A11, -B8, -A2.1, and p210 BCR-ABL b3a2 expression. EBV-transformed lymphoblastoid B cell lines were established from PBLs by the standard method.
CML blasts were obtained with informed consent after leukopheresis from patients in myeloid blast crisis. Immunophenotypic analysis of PBMCs showed CD2
, and CD34 ϩ ( Ͼ 85%). The CML cells from patients collected by leukopheresis were all Ͼ 90% positive for expression of CD34 ϩ and HLA class I ϩ antigens, with side and forward scatter measurements consistent with a blast cell population. Reverse transcriptase PCR using bcr-abl -specific primers were used to confirm the b3a2 translocation. CML tumor cells were cultured in complete RPMI 1640 medium (1 mM sodium pyruvate, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FCS) supplemented with the following growth factors: GM-CSF (10 ng/ml), stem cell factor (80 ng/ml), IL-3 (20 ng/ml), and erythropoietin (3 U/ml Peptides and peptide binding assays. HPLC-purified peptides were purchased from Neosystem (Strasbourg, France). BCR-ABL b3a2 junction peptides are listed (see Table I ). HIV1 polymerase peptide (LDTGADDTV) and influenza virus matrix peptide 58-66 (GILGF-VFTL) were used as a control. BCR-ABL b3a2 junction peptide binding capacities were evaluated in inhibition assays using the 125 I-labeled hepatitis B virus core 18-27 peptide (HBc18-27, FLPSDYFPSV, F10V) as control, and soluble HLA-A2.1 molecules. Thermostabilization assays were performed, using T2 cells grown for 48 h at 26 Њ C in a serum-free medium in the presence of 20 mM peptide. Cells (3 ϫ 10 5 ) were then shifted to 37 Њ C for 3 h (22) . Expression of HLA-A2.1 was measured by flow cytometry using the anti HLA-A, -B, and -C W6.32 mAb on a Becton Dickinson cytofluorometer (San Jose, CA).
Peptide stripping. Cells were pelleted and gently resuspended in 0.5 ml of stripping buffer (0.13 M citric acid, 66 mM Na 2 HPO 4 , 150 mM NaCl, and 17 g/ml phenol red). After 30 s, the cell suspension was neutralized by dropwise addition of 0.3 ml of a saturated solution of Na 2 HPO 4 containing the indicated peptide concentration.
In vitro CTL response induction and 51 Cr-release assay. CTL induction was performed as described previously (23, 24) . Briefly, PBL from HLA-A2.1, -A11, -A3, or -B8 healthy donors or CML patients were incubated with concanavalin A and rIL-2, to induce T lymphoblasts. These lymphoblasts were then peptide-stripped as indicated above and loaded with the desired peptide. These peptide-loaded irradiated lymphoblasts were added to CD8 ϩ -enriched PBLs of the same donor in T cell culture medium containing rIL-2 (10 U/ml) and rIL-7 (30 U/ml). T cells were expanded through weekly restimulation with autologous, peptide-loaded monocytes, rIL-2 (10 U/ml), and rIL-7 (30 U/ml). Depending on the frequency of specific CTL precursors, effector cells were expanded for variable periods of time in vitro before specific lytic activity could be detected.
The cell-mediated cytolytic activity in cultures was detected in a 6-h Cr-labeled, peptide-loaded target cells (10 4 per well) were added in a final volume of 200 l. Each dilution was tested in 24 replicated wells. Supernatants were collected after 9 h of incubation at 37 Њ C. A well was considered positive if the 51 Cr-release was Ͼ 3 SD above the mean release of control wells containing target cells alone. Effector cell frequencies were estimated by a Poisson distribution analysis (25) . Minimal estimates were verified by using the statistical method of 2 minimization, applying Poisson probability theory to the single hit model (26). For the sake of comparison, CTL frequencies are standardized in the text to the number of CTL per 10 4 lymphocytes.
Results
A BCR-ABL b3a2 junction peptide binds and stabilizes thermolabile HLA-A2.1 molecules. Seven peptides encoded in the fusion region of p210 BCR-ABL b3a2 (Table I) were tested for their capacity to bind to HLA-A2.1 ϩ T2 cells in a previously described thermostabilization assay (22) . T2 cells are defective in both TAP1 and TAP2 peptide transporters, resulting in cell surface expression of unstable MHC class I molecules deprived of peptide. Stabilization can be artificially obtained by culturing T2 cells at 26 Њ C. Fixation of exogenous peptides results in complete stabilization of MHC class I molecules which can be evaluated after incubation at 37 Њ C. Using this assay, four of seven peptides tested induced a significant stabilization of HLA-A2.1 molecules at the cell surface (Fig. 1) . One of them, SSKALQRPV (S9V), exhibited significant binding avidity in a competition assay with the standard HBc 18-27 (F10V) peptide and allowed substantial stabilization of HLA-A2.1 molecules at the surface of T2 cells after 3 h, a delay which should be sufficient for efficient engagement with the T cell receptors (Table II) .
Induction of BCR-ABL b3a2 junction peptide-specific primary CTL responses from healthy donors. We and others reported previously that primary CTL could be generated in vitro against peptides in mice and humans (23, 24) . In this study, we used the HLA-A2.1-binding S9V nonapeptide and the four previously identified HLA-A3, -A11, or -B8 binding BCR-ABL b3a2 -derived junction peptides to elicit CTL in vitro. Primary CTL were induced from PBL of HLA-matched healthy donors using peptide-loaded autologous lymphoblasts as stimulator cells. Assaying these in vitro stimulated lymphocytes against peptide-pulsed, HLA-matched, EBV-transformed target cells, specific lysis was obtained in three of five HLA-A11, in two of five HLA-A3, in two of four HLA-B8, and in two of six HLA-A2.1 donors. These CTL are specific for BCR-ABL since they do not recognize HLA-matched, EBV-transformed target cells pulsed with the irrelevant HIV1 polymerase and influenza peptide (Table III , row 2) (Fig. 2 a) . These CTL have classical CD8 ϩ phenotypes (data not shown) and, as illustrated in Fig. 2 a and -positive tumor cells was observed in five of the seven tested CTL lines. More interestingly, specific recognition of HLA-matched tumor cells, endogenously expressing the BCR-ABL b3a2 chimeric molecules, was observed, whichever the tested class I restricting molecule (Fig. 2, a and b) (Table III) . Therefore, the BCR-ABL b3a2 molecule is effectively intracellularly processed and natural peptides, similar to the synthetic ones, are presented by the corresponding HLA class I molecules on the cell surface. Some CTL lines (usually of lower lytic capacity) failed to recognize the tumor target cells, suggesting either limited cell surface presentation of the junction peptides or low TcR affinity.
In vitro induction of BCR-ABL b3a2 junction peptide-specific CTL responses in CML patients. Having established that BCR-ABL junction peptides can induce in vitro CTL responses from the PBL of healthy donors, and that identical peptides Table I , were tested for their capacity to stabilize HLA-A2.1 molecules expressed at the surface of T2 cells using the W6/32 mAb as described in Methods. Mean fluorescence intensity is expressed in arbitrary units (A.U.). ND ND 55  45  40  32  25  8  3  0  35  22  HLA-mismatched  tumor cell  12  3  5  2  ND ND ND ND 22  8  12  8  3  2  3  1  8  3 CTL lines, derived by in vitro stimulation of PBL from healthy donors with autologous T cell blasts pulsed with BCR-ABL b3a2 junction peptides were tested against EBV-transformed autologous target cells pulsed either with the relevant BCR-ABL b3a2 junction peptide (row 1), or the irrelevant HIV polymerase peptide (row 2). These CTL lines were similarly tested against autologous (row 3) and HLA-mismatched, BCR-ABL b3a2 -positive CML leukemic cells (row 4). Percentages of specific killing are given for two effector-to-target ratios (30:1, 10:1). ND, not determined.
were naturally produced in BCR-ABL b3a2 -positive cells, we next tested whether similar responses could be induced from the PBL of CML patients. Autologous, peptide-loaded blast cells or patients' dendritic cells, which express the chimeric protein, were used as stimulators. Using this approach, specific CTL could be in vitro-stimulated from PBL of 2 of 4 HLA-A3, 2 of 7 HLA-B8, and 3 of 10 HLA-A2.1 CML patients (Table  IV) . Lysis was observed with peptide-pulsed autologous EBVtransformed cells (Table IV, Cr-labeled autologous tumor cells, cold target inhibition of lysis was observed with T2 cells loaded with the S9V BCR-ABL but not with a control influenza peptide (Fig. 3 c) , and with BCR-ABL b3a2 positive K562 cells expressing HLA-A2.1 molecules (Fig. 3 b) but not with K562 cells expressing HLA-B8 molecules and the CML-B8 ϩ cells (Fig. 3 b) . A reverse pattern of inhibition was observed, assaying HLA-B8-restricted, BCR-ABL-specific CTL and HLA-B8-, HLA-A2.1-transfected K562 cells, or CML-A2 ϩ cells (Fig. 3 a) . Together, these results indicate that BCR-ABL-specific CTL responses can be stimulated in vitro using patients' PBL and autologous, peptide-loaded cells. They further confirm that endogenous processing of BCR-ABL b3a2 molecules results in cell surface presentation, by HLA-A2.1, -A3, and -B8 molecules, of antigenic junctional peptides similar to those defined by the binding and stabilization experiments. Since these peptides are presented on the surface of the leukemic cells, we next questioned whether these cells could be immunogenic in vivo.
Specific BCR-ABL CTL detected in vivo in 5 of 21 CML patients. Limiting dilution analysis was performed to determine the frequency of specific CTL in PBL of CML patients. High frequencies of BCR-ABL b3a2 -specific CTL were found in 5 of 21 CML patients compared to healthy donors (Table V) . In contrast, no meaningful differences in influenza virus-spe- -ABL peptide  75  45  45  25  35  15  25  15  38  25  48  30  50  25  HLA-matched EBV cells  with HIV peptide  25  10  8  3  10  3  12  8  15  7  12  7  15  5  Autologous tumor cells  50  25  9  6  25  15  30  22  8  3  35  28  7  6  HLA-mismatched tumor cells  10  8  8  5  5  4  6  8  5  2  7  6  4  5 PBL from CML patients were stimulated in vitro four times with autologous T cell blasts pulsed with BCR-ABL b3a2 junction peptides. CTL lines were tested against EBV-transformed autologous target cells pulsed with either the relevant BCR-ABL b3a2 junction peptides listed (Table I, cific CTL frequencies were detected between the CML patients and the healthy donors. These specific CTL were detected using peptide-pulsed syngeneic EBV-transformed cells. To eliminate a potential autoreactivity and to evaluate the in vivo potential of BCR-ABL-specific CTL, limiting dilution assays were performed using either autologous CML, autologous EBV, or autologous normal B cells as target cells. These last two cells were tested and found negative for the expression of BCR-ABL. A higher CTL frequency was found on the autologous CML cells compared to autologous EBV-transformed cells or normal B cells (Table VI) . This result indicates that some CML patients spontaneously generated CTL responses against the BCR-ABL b3a2 translocation product.
Discussion
This study identifies, for the first time, an HLA-A2.1-restricted peptide from the BCR-ABL b3a2 junctional region which (a) binds to HLA-A2.1 molecules, (b) stimulates in vitro-specific CTL responses using PBL from both healthy donors and CML patients, and (c) is spontaneously processed and presented at the surface of CML cells. Such presentation results, for certain patients, in a sizable expansion of CML-specific CTL. Similar parallel studies with other BCR-ABL b3a2 junction peptides presented by other MHC class I alleles led to the same observations. Considering the large representation of these HLA class I alleles (for example, HLA-A2.1 is found in 40% of individuals), these results might be of general immunotherapeutic interest.
Using a similar approach, other groups searched for BCR-ABL b3a2 -derived peptides and failed to find any strong binder to HLA-A2.1 molecules (18) (19) (20) (21) . This is probably due to the fact that the peptide identified in this study does not exhibit the consensus HLA-A2.1 binding motif. It should be further pointed out that the binding and thermostabilization assay of HLA molecules which we used, at 26ЊC in serum-free medium, is very sensitive. Thus, as noted by others, a search for antigenic peptides should not be limited to peptides displaying canonical motifs (27), since secondary anchor residues can compensate for the absence of the major ones. Additionally, some low affinity peptides have been proved immunogenic when help is provided and if presentation is insured by appropriate antigen-presenting cells (28) . One should also note that a small number of specific MHC/peptide complexes on target cells is sufficient for recognition by activated T cells (29, 30) .
Certain BCR-ABL b3a2 -specific, in vitro-induced CD8 ϩ CTL lines from different individuals were able to lyse either HLA-matched, transfected K562 (BCR-ABL b3a2 positive), or autologous CML leukemic cells. This indicates that the p210 BCR-ABL b3a2 fusion molecules can be processed by tumor cells with efficient surface antigenic peptide presentation by either HLA-A3, -A11, -A2.1 or -B8 class I molecules. However, in ‫ف‬ 75% of cases, we failed to elicit, in healthy donors as well as in CML patients, in vitro-sizable CTL responses, even when tested with peptide-pulsed, EBV-transformed sensitive target cells. Additionally, we observed frequently less efficient lysis of BCR-ABL b3a2 tumor cells (which only present peptides endogenously processed). Many reasons might explain such observations. BCR-ABL-processed peptides might be expressed in relatively low amount on cell surfaces. In vitro induction of CTL from a few million T lymphocytes might often result in the stimulation of CD8 ϩ T lymphocytes of lower affinity than responses developing in vivo, assuming high affinity clones to be of low frequencies. Finally, it is possible, as often documented, that in patients, specific CTL clones could be anergized, even deleted leukemic cells lacking some essential costimulatory molecules or secreting inhibitory cytokines (31, 32) . However, there are ways to circumvent these difficulties. The amount of HLA class I antigenic peptide complexes required for target cell recognition is lower than the amount required for CTL induction. Loading exogenously dendritic cells with synthetic peptides or transfecting them with potent expressing vectors, limited to the BCR-ABL b3a2 junction region, should improve the CML patient leukemia-specific CTL responses. Successes with the later approach have been reported recently in animal experimental systems, even at advanced stages of tumor development. In this line of thinking, one should stress that the BCR-ABL b3a2 junction peptides are not self, minimizing the risk of autoimmunity. Significantly, circulating CTL in patients show no detectable toxicity in vivo towards normal tissues. However, this does not exclude the possibility, since the BCR-ABL protein is overexpressed in CML, that other CML-specific T cells directed against cryptic or subdominant BCR or ABL peptides could also be stimulated in the respect of normal cells, as established in certain mouse studies (33, 34) .
Although a larger number of patients needs to be evaluated to reach a general conclusion, this study establishes that BCR-ABL-specific CTL exist at a high frequency in ‫ف‬ 25% of the leukemic patients, therefore, suggesting an active specific immune surveillance against CML. Thus, one might hope that the stimulation or reactivation of such responses in patients undergoing monoclonal expansion during the acute late phase of CML could have a significant therapeutical interest.
It is likely that the BCR-ABL protein is present in the earliest pluripotent malignant progenitor undergoing monoclonal expansion in CML patients (35) (36) (37) . Only rarely do Ph1 ϩ CML become Ph1 Ϫ , and only rarely do Ph1 ϩ CML lose detectable BCR-ABL fusion transcripts during disease progression (38) . Since the BCR-ABL protein is intimately associated with transformation (35), antigen-negative variants, which might result from immunization, should not have a malignant phenotype. In view of our results, adoptive T cell immunotherapy and peptide-based vaccination are both conceivable in patients with CML. Cr-labeled BCR-ABL b3a2ϩ CML autologous tumor (row 1), BCR-ABL b3a2Ϫ autologous EBV-transformed (row 2), and autologous normal B cells (row 3).
